"Pharmaceutical Speed Reader" 2020 edition of the Chinese Pharmacopeia promulgated the second domestic two-price HPV vaccine reported.

the 2020 edition of the Pharmacopoeia of the People's Republic of China, the second batch of two-month Abitron procurement volume has been completed nearly seven times, Mylan shareholders through a merger with Puqiang new company Viatris is expected to be established in the fourth quarter, the United States to buy Ridsiwe production in the next three months, Johnson's Ebola vaccine program was approved by the European UnionOn the 2nd, the State Drug Administration and the State Health and Care Commission issued a public announcement, officially promulgated the 2020 edition of the "People's Republic of China Pharmacopoeia", a total of 5911 varieties, 319 new species, revised 3177 species, no longer load 10 species, varieties adjusted and combined 4 speciesThis edition of the Pharmacopoeia will be officially implemented on December 30 this year(National Drug Administration)1, the Beijing Municipal Health Insurance Bureau issued "on the submission of the third batch of state-organized drug centralized procurement of varieties pre-procurement volume notice", said that according to the national medical security bureau unified work deployment, to carry out the third batch of national procurement of varieties pre-procurement volume reporting work, the reporting time is July 2 10:00 to July 8 16:00(
) on the 1st of, Jiangxi Province Pharmaceutical Procurement Service Platform informed the second batch of state-organized drug centralized procurement and use of Jiangxi's selected results of 32 drug procurement progress and related informationIn less than two months, Abitron (0.25g) has reached 696.92% of the completion rate; Adfovir is also more than 200% of the scheduleThe total quantity of the 36 product regulations in the province accounted for 57.08 percent of the total purchase(
)in accordance with the "State Drug Administration Announcement on the Implementation of <> Related Matters" (No46 of 2020), in order to promote the drafting and formulation of relevant supporting normative documents and technical guidelines, under the deployment of the State Drug Administration, the Drug Administration organization has formulated the "Safety Information Assessment and Management Code for Drug Clinical Trials (Trial)", effective July 1, 2020(CDE)in order to implement the relevant provisions of the Drug Administration Law and strengthen the record and data management of drug development, production, operation and use activities, on July 1, the State Drug Administration issued the Drug Records and Data Management Requirements (Trial), effective December 1, 2020(
) myblue announced that its shareholders voted overwhelmingly at the company's special general meeting to merge myblue and Pfizer's ProGen The new company, Viatris, is expected to open in the fourth quarter of this year Viatris will also launch a new and unique GLOBAL HEALTHCARE GATEWAY service The U.S government has reached a procurement agreement with Gilead Sciences to buy out almost all of Redsewe's supply over the next three months, according to a recent report by the foreign media pharmaphorum.com, This means that for at least the next three months, the UK, the EU and other countries will not be able to buy Ridsewe, or face the embarrassment of being almost "drug-free" (Sina Pharmaceutical News) 1, Sessen Pharmaceuticals and EpicentRx announced the agreement on tumor immunotherapy RRx-001 exclusive license agreement in Greater China, involving up to $120 million This is a small molecular immunotherapy targeting CD47-SIRP alpha and is currently undergoing phase 3 clinical trials for small cell lung cancer indications July 1 local time, Johnson and Johnson announced that its Jansen Pharmaceuticals dual-measurement package for Ebola vaccines, Zabdeno ® (Ad26.ZEBOV) and Mvabea ® (MVA BN Filo) have been approved by the European Commission for active immunization to prevent Ebola virus infection in individuals 1 year and older in the Democratic Republic of the Congo (Sina Pharmaceutical News) FDA recently issued a warning letter that the website of a Company of SuperHealthGuard and Loyal Great International Ltd in Hong Kong, China, can sell the capsules to the United States, directly labeling the product is intended to alleviate, prevent, treat, diagnose or cure COVID-19 content, there is some misleading (Pharma Rubik's Cube) Pfizer and BioNTech announced that the new mRNA-based vaccine developed by the two countries has achieved positive results in Phase 1/2 clinical trials After two vaccinations, the neutralizing and antibody titer of the new coronavirus in the patients who received the 10?g and 30 sg doses of the vaccine reached 1.8 and 2.8 times the serum level of the recovered patients, respectively The preliminary results of this clinical trial were also published in the preprinted website medRxiv (Pharmaceutical seaching) , Akero Therapeutics inc announced its treatment of non-alcoholic fatty hepatitis (NASH) in the research therapy eluxifermin (EFX), in a Phase 2a clinical trial in the 16-week mid-week results analysis It is worth noting that 48% of the 40 patients who received tissue biopsies after treatment achieved at least one level of improvement in liver fibrosis and at least two levels of fibrosis in the absence of a deterioration in the non-alcoholic fatty liver disease activity score (NAS) (Pharmaceutical MingKangd) Hualead Pharmaceuticals recently announced the positive results of its 24-week core clinical study of the world's first new drug, glucose kinase activator dorzagliatin, and metformin (global first-line drug for type 2 diabetes) On the 1st of , the AMG 910 clinical application submitted by Amjin/Baiji Shenzhou was accepted by CDE The drug is currently in the clinical phase of stage I of gastric cancer or gastric esophagus cancer worldwide The AMG 910 is a CD3/CLDN18.2 bispecific antibody CLDN18.2 is a protein encoded by the CLDN 18 gene that belongs to a closely connected family of cells that controls the molecular flow between layer cells (Pharmarubik) Baiji Shenzhou announced that the Drug Review Center of the State Drug Administration has accepted its application for the listing of new indications for patients with non-removable hepatoblastoma, the anti-PD-1 antibody drug Bezean ® (Forrelizhu monosystalysis injection) that have previously been treated 1, Sichuan sane 1 new drug injection with recombinant human tumor necrosis factor-related apoptosis-tripolymer fusion protein (SCB-313) clinical application was accepted by CDE, acceptance number CXSL2000184 Minne net data show that the new class 1 drug has been carried out in the country 3 indications of phase I clinical, this is expected to be the new indications declared clinical (Minnet.com) according to CDE official website, Yuxi Zerun Biotechnology Co., Ltd reorganizing the human papillomavirus double price (16/18 type) vaccine (yeast) listing application was accepted, which means that the second domestic two-price HPV vaccine reported production, domestic HPV vaccine is expected to usher in a new spoiler (CDE) a new paper published online in nature, a leading academic journal, showing the potential for long-term treatment of HIV infection with a new small molecule drug developed by the biopharmaceutical company Gilead Sciences Preliminary clinical studies showed that after a single dose of the drug, hiv-infected people had reduced viral load in the body, and the drug remained active in the body after more than 6 months of injection (Academic latitude)